ARCHIVES

Zelboraf Increased Overall Survival To 15.9 Months in Phase II Study

This article is from The Cancer Letter archive.

Vol. 35 No. 3 | March 30, 2012

Download PDF Visit The Full Archive

Related Articles

DCT Board Approves Recompetition Of Drug Development Contracts

June 25, 1993

Trial Data: No Benefit In Adding Perifosine to Capecitabine

June 29, 2012

Nearly 3,000 certified As Oncology Nurses

January 8, 1988

Investigation finds no evidence FDA’s Crawford had affair with subordinate.

June 10, 2005

NTP Committee Accepts Industry Positions On Policy To Separate Figures for Benign, Malignant Lesions

November 7, 1980

In Brief: Tormey To Replace Carbone As ECOG chairman; Bishop Delivers First B.J. Kennedy Lecture

November 2, 1990